Skip to main content

IMI impact on patient involvement - event

For many years, patient involvement in research was restricted to participating in clinical studies and trials as research subjects. Today, it is widely recognised that patients can and should be much more involved in all aspects of research, including agenda setting, study design, communication, and ethics.

patient hands picture

About this event

For many years, patient involvement in research was restricted to participating in clinical studies and trials as research subjects. Today, it is widely recognised that patients can and should be much more involved in all aspects of research, including agenda setting, study design, communication, and ethics. At the same time, researchers are now well aware that patients bring unique knowledge and skills to projects which can help to improve the quality of research. At IMI, we seek to encourage patient involvement in all our activities, and many projects already have patients on board. We also involve patients as speakers and panellists in our events and encourage their participation in consultations.

This event is part of  a series of  live sessions that IMI is organising on IMI Impacts, where key actors explore the biggest challenges in their respective fields and demonstrate how IMI contributed to addressing them. During these sessions, we also focus on patients’ testimonies, as they are the ultimate beneficiaries of IMI’s funded research.

Furthermore, we want to engage IMI stakeholders in a broader discussion on IMI’s impact. With this initiative, we want to demonstrate the successful IMI model of radical collaboration.
 

Agenda and presentations

 

Welcome and introduction

Elli Karagianni, Scientific Project Officer, IMI - recording and presentation

 

The challenge, the vision and the value

Jan Geissler, PATVOCATES - recording and presentation

 

How IMI projects have addressed the challenge & 'moved the needle' , Solutions from IMI projects

 

Q&A time 

  • This document sets out IMI's responses to questions that, due to time constraints, could not be addressed during the webinar. View the recording here.
 

Closing remarks 

Magda Chlebus, Executive Director, Science Policy & Regulatory Affairs, EFPIA